PNPLA5

Across TCGA pan-cancer cohorts, PNPLA5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PNPLA5 data layer compared with 15 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PNPLA5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PNPLA5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where PNPLA5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.857	0.222	<.001	21	view →
PDAC	DFS	Median	II,III,IV	0.314	0.485	.025	10	view →
LSCC	OS	Median	II,III,IV	1.000	0.904	.033	6	view →
HNSC	OS	Median	IV	0.951	0.695	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PNPLA5–LUAD (DFS)

Open the LUAD breakdown →